Sign In
Buy SGHT
$4.34
+0 (+0%)
At Close: Jun 03, 2026
Sight Sciences Announces the Release of its First Sustainability Report
04:05pm, Monday, 10'th Jun 2024
The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Co
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvem
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The ana
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
01:58am, Sunday, 05'th May 2024
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Of
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
07:20pm, Thursday, 02'nd May 2024
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
04:05pm, Thursday, 02'nd May 2024
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing in
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, i
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
04:05pm, Thursday, 18'th Apr 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commerci
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
04:05pm, Wednesday, 10'th Apr 2024
The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes The eff
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease.
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
04:05pm, Tuesday, 26'th Mar 2024
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commerci
Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript
10:56pm, Thursday, 07'th Mar 2024
Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder & Chief Exe
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
06:51pm, Thursday, 07'th Mar 2024
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
04:05pm, Thursday, 07'th Mar 2024
MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
04:05pm, Thursday, 22'nd Feb 2024
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercia
